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Intense efforts are underway to evaluate potential therapeutic agents for the treat-
ment of COVID-19. In order to respond quickly to the crisis, the repurposing of exis-
ting drugs is the primary pharmacological strategy. Despite the urgent clinical need
for these therapies, it is imperative to consider potential safety issues. This is impor-
tant due to the harm–benefit ratios that may be encountered when treating COVID-
19, which can depend on the stage of the disease, when therapy is administered and
underlying clinical factors in individual patients. Treatments are currently being
trialled for a range of scenarios from prophylaxis (where benefit must greatly exceed
risk) to severe life-threatening disease (where a degree of potential risk may be toler-
ated if it is exceeded by the potential benefit). In this perspective, we have reviewed
some of the most widely researched repurposed agents in order to identify potential
safety considerations using existing information in the context of COVID-19.
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1 | INTRODUCTION
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a
highly pathogenic betacoronavirus that emerged in Wuhan, Hubei
Province, in late December 2019 (Yang, Liu, et al., 2020; Yang, Yu,
et al., 2020). SARS-CoV-2 is the seventh human coronavirus (HCoV)
to be identified and is the cause of the disease known as COVID-19,
which was declared by the World Health Organization (WHO) as a
“Public Health Emergency of International Concern” on January
30, 2020 (Liu, Hu, et al., 2020). The symptoms of COVID-19 are non-
specific and cover a broad clinical spectrum, meaning that clinical
diagnosis without a test is challenging. Patients commonly present
with fever, cough, and anosmia, although many patients are asymp-
tomatic. The virus can be transmitted by asymptomatic patients
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alongside those in the symptomatic and pre-symptomatic phase of
the disease (Wu, Wu, Liu, & Yang, 2020; Yang, Yu, et al., 2020). As of
July 8, 2020, COVID-19 was responsible for 539,057 deaths world-
wide (John Hopkins University and Medicine, 2020). As the number
of new cases continues to increase rapidly, many clinical and preclini-
cal studies have been initiated to identify viable treatment options for
COVID-19 patients. Many of these potential therapeutic strategies
are based upon the repurposing of approved drugs or the evaluation
of those currently in the clinical stages of drug development
(Figure 1). For this reason, much information already exists on the
pharmacology and toxicology of each prospective therapy. In order to
examine their potential for efficacy and safety against COVID-19, it is
essential to consider all of the available information in this extremely
fast-moving and critical research field. Therefore, it is important to
assess drug-specific safety parameters in the context of the pathogen-
esis of the virus and its clinical features in order to begin to evaluate
the disease-specific harm–benefit ratio.
Therapeutic strategies for the treatment of COVID-19 span a
range of phases including prophylactic administration, through to early
infection, through to the more severe disease stage characterised by
pulmonary involvement requiring mechanical ventilation and hyper-
inflammation in some instances (Siddiqi & Mehra, 2020). At the time
of writing, over 2,400 clinical trials have been initiated across the
globe, with the majority of these investigating the use of drug(s)
already approved for treatment of another disease (ClinicalTrials.gov,-
2020b). In addition to administration as a monotherapy, combination
therapy has also been utilised. In addition to repurposed compounds,
several candidates in preclinical or clinical development stages are also
under investigation, as well as widely available borderline substances
such as ascorbic acid (ClinicalTrials.gov, 2020d). However, it is
important to note that the number of clinical trials initiated should not
be taken as an indicator of the ultimate potential for success.
Our perspective will focus upon selected repurposed therapies,
which are used in different phases of the disease (Figure 1) and can
broadly be categorised by their mechanism of action as (a) viral entry
inhibitors, (b) disruption of cellular viral processing, (c) modulators of
the inflammatory phase, and (d) compounds that stimulate the host's
antiviral response. Selections were based upon agents undergoing the
largest clinical trials at the time of writing, July 8, 2020.
2 | INHIBITORS OF ENTRY INTO
EPITHELIAL CELLS
It has been widely reported that ACE2 is likely to be the predominant
cell surface receptor by which SARS-CoV-2 is able to enter host cells
(Hoffmann et al., 2020). ACE2 is widely distributed in the body, but is
particularly highly expressed on lung alveolar cells, which could
explain the increased lung damage seen in some COVID-19 patients
(Favalli et al., 2020; Zhao et al., 2020).
2.1 | Angiotensin receptor blockers
Losartan is an antagonist of AT1 receptors, one of the angiotensin
receptor blockers (ARBs) widely used as anti-hypertensive drugs. In
the present context, losartan is hypothesised to block the attachment
of SARS-CoV-2 to cells expressing ACE2, thereby preventing viral
entry into host cells (Gurwitz, 2020). Losartan is a well-tolerated com-
pound used in the treatment of hypertension, heart failure and
F IGURE 1 Overview of the mechanisms of action of the repurposed drugs undergoing clinical trials for the treatment of COVID-19 that are
reviewed here. Compounds in red represent those that are viral entry inhibitors, compounds in green represent disruptors of cellular viral
processing, compounds in blue are modulators of the hyperinflammatory phase of infection, and compounds in yellow stimulate host
immunomodulatory and antiviral activity. ISRE, IFN-stimulated response element; P, phosphate; RdRp, RNA-dependent RNA polymerase; SARS-
CoV-2, severe acute respiratory syndrome coronavirus 2
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diabetes (Goa & Wagstaff, 1996; Ripley & Hirsch, 2010). For these
indications, losartan treatment is lifelong and is typically administered
at a dose of 25–50 mg once a day, which can be increased to 100 mg
if tolerated and deemed necessary (Dohme, 2003). Clinical trials for
losartan use in COVID-19 are currently recruiting patients. While
exact dosing regimens vary between the trials, they are based upon
the standard dose and will see patients given 25–50 mg daily losartan
treatment for 7–14 days (Clinical Trial Identifiers NCT04335123,
NCT04312009, and NCT04311177).
When used for its intended therapeutic conditions, losartan is
considered to be a relatively safe compound. The most common
adverse events (AEs) reported during clinical trials were headache, diz-
ziness, fatigue, and hypotension (Goa & Wagstaff, 1996; Usai
et al., 2020; Weber, 1997). Laboratory findings during clinical trials
reported mild elevations in alanine aminotransferase (ALT), but these
were self-limiting and did not result in acute liver failure (Goa &
Wagstaff, 1996). More recently, cases of losartan-induced hepatotox-
icity have been reported, albeit rarely (LiverTox, 2017a). Losartan is
associated with serious cases of fetal toxicity and so cannot be admin-
istered to women in the second and third trimesters of pregnancies
(Nayar, Singhal, Aggarwal, & Malhotra, 2003).
There is controversy regarding the use of losartan in COVID-19
trials as the expression of ACE2 can be significantly increased follow-
ing ARB treatment. However, contradictory results for the potential
of ARB-induced ACE2 up-regulation have also been reported (Ferrario
et al., 2005; Klimas et al., 2015; Tignanelli et al., 2020). Given that
ACE2 is already highly expressed within the lungs, a further increase
in ACE2 expression may have the potential to increase viral entry into
the lungs, thus exacerbating the potential for pulmonary involvement
(Fang, Karakiulakis, & Roth, 2020). Evidence of increased myocardial
injury and chronic damage to the cardiovascular system has been
reported in patients infected with SARS-CoV-2 (Zheng, Ma, Zhang, &
Xie, 2020). ACE2 is also expressed within the cardiovascular system,
and it has been suggested that this may underlie cardiac effects via
enhanced viral entry into the myocardium (Zheng et al., 2020). It is
important to note that human data thus far do not support the
hypothesis that ARBs (and ACE inhibitors) increase the risk of severe
COVID-19 disease because epidemiological studies have largely
shown either a protective effect or no adverse effects on mortality in
COVID-19 (Tignanelli et al., 2020). Importantly, the latest advice from
the Medicines and Healthcare products Regulatory Agency
(MHRA, 2020a) recommends that those taking ARBs and ACE inhibi-
tors for high BP should continue doing so. Data from clinical trials for
losartan in COVID-19 will provide additional safety data and much
needed clarification on the role of ARBs and ACE2 in COVID-19.
Losartan has an overall favourable drug–drug interaction (DDI)
profile. However, concerns over the use of losartan and non-steroidal
anti-inflammatory drugs (NSAIDs) during COVID-19 treatment have
been raised (Sica, Gehr, & Ghosh, 2005). Evidence initially suggested
that there was a theoretical potential for NSAIDs to worsen COVID-
19 symptoms. However, the Commission on Human Medicines
deemed that there was insufficient evidence to confirm this associa-
tion and that NSAIDs were safe to use in individuals with
symptoms of COVID-19 (Commission on Human Medicines, 2020;
Torjesen, 2020). However, NSAIDs have the potential to attenuate
the effects of losartan to reduce hypertension, thereby leading to an
increase in BP, which would be an undesirable side effect in COVID-
19 patients with hypertension, lung inflammation, and cardiac damage
(Pavlicevic, Kuzmanic, Rumboldt, & Rumboldt, 2008). In such patients,
BP should be closely monitored.
3 | DISRUPTORS OF CELLULAR VIRAL
PROCESSING
3.1 | Lopinavir–ritonavir
Lopinavir–ritonavir is a fixed dose combination of anti-viral drugs
branded as Kaletra® and developed for the treatment of human
immunodeficiency virus (HIV) disease. Lopinavir is a protease inhibitor
that is co-administered with ritonavir to improve the pharmacokinetic
(PK) properties of the drug (Chu et al., 2004). Lopinavir–ritonavir is a
potential treatment for COVID-19 as it targets and deactivates the
SARS-CoV-2 main protease (Mpro), which is involved in polyprotein
processing and virus maturation (Dayer, Taleb-Gassabi, &
Dayer, 2017). A standard dose of lopinavir–ritonavir is 400/100 mg
twice a day for HIV-1 treatment, and this has also been used for
SARS-CoV-2 treatment (Cao et al., 2020).
The most frequently reported AEs for lopinavir–ritonavir treat-
ment are gastrointestinal disturbances including diarrhoea, nausea,
and vomiting (Chandwani & Shuter, 2008). Dose-related diarrhoea has
been reported in up to 25% of patients and is thought to occur
through a number of mechanisms including decreased proliferation of
intestinal epithelial cells, disruption of intestinal barrier function,
inducing endoplasmic reticulum stress, and activating the unfolded
protein response (Wu, Li, Peng, & Zhou, 2014). Diarrhoea is also a
symptom in some COVID-19 patients, and so lopinavir–ritonavir has
the potential to exacerbate this. Pancreatitis has been reported in a
small number of patients following lopinavir–ritonavir treatment,
although this was more frequent in those with a pre-existing history
of pancreatitis (Chandwani & Shuter, 2008; Oldfield & Plosker, 2006).
Additionally, patients with underlying liver diseases should have regu-
lar monitoring of hepatic function (Palacios et al., 2006). Caution
should be exerted for those patients taking concomitant medication
as lopinavir–ritonavir inhibits P-glycoprotein (P-gp) and cytochrome
P450 (CYP)-3A4, which therefore may alter the PK of other com-
pounds (Zhang, Zhang, & Huang, 2009). A COVID-19 drug interaction
website has been developed by the Liverpool Drug Interaction Group,
which details the drug–drug interactions (DDIs) found with lopinavir–
ritonavir and a number of drugs, which in some cases can lead to
potentially serious and/or life-threatening reactions (AbbVie
Inc., 2016; Liverpool Drug Interaction Group, 2020).
Since the SARS-CoV-2 outbreak, 79 clinical trials have been regis-
tered (up to July 8, 2020) to test lopinavir–ritonavir as a potential
treatment for SARS-CoV-2 with variable outcomes in terms of effi-
cacy. In one trial of 199 patients with confirmed SARS-CoV-2,
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13 patients on the lopinavir–ritonavir arm were withdrawn due to AEs
(Cao et al., 2020). In a different trial, patients who were administered
with lopinavir–ritonavir (200/50 mg) also experienced gastrointestinal
AEs (Li et al., 2020).
3.2 | Chloroquine and hydroxychloroquine
Chloroquine and its derivative, hydroxychloroquine, are widely used
as inexpensive and safe antimalarial drugs. In particular, the
established good tolerability of chloroquine/hydroxychloroquine has
made them safe to use even in pregnancy (Villegas et al., 2007). In
addition to antimalarial activity, both drugs have immunomodulating
effects and are used for the treatment of autoimmune diseases includ-
ing systemic and discoid lupus erythematosus, psoriatic arthritis and
rheumatoid arthritis. Chloroquine/hydroxychloroquine concentrates
extensively in acidic vesicles including the endosomes, Golgi vesicles,
and the lysosomes (Ohkuma & Poole, 1981). This leads to lysosomal
membrane permeabilisation or dysfunction of several enzymes includ-
ing acid hydrolases and palmitoyl protein thioesterase 1 (Rebecca
et al., 2019; Savarino, Boelaert, Cassone, Majori, & Cauda, 2003;
Schrezenmeier & Dorner, 2020). Although the precise mechanisms of
the antiviral effects are not fully understood, it has been proposed
that chloroquine/hydroxychloroquine can prevent virus infection (pre-
infection) by interfering with the glycosylation of cellular receptors
and impair viral replication by increasing endosomal pH (post-infec-
tion) (Savarino et al., 2003; Savarino et al., 2004; Vincent et al., 2005).
Owing to their efficacy against viruses (mostly demonstrated
in vitro) including influenza, HIV, coronavirus OC43, and SARS-
CoV, a large number of clinical trials (>230) have been registered
worldwide using chloroquine/hydroxychloroquine alone, or in com-
bination with other drugs (e.g., azithromycin) for the treatment of
COVID-19. Despite promising in vitro antiviral results for
hydroxychloroquine/chloroquine, there is no convincing evidence of
efficacy in vivo at present (Gao, Tian, & Yang, 2020; Gautret
et al., 2020a; Gautret et al., 2020b; Liu et al., 2020; Magagnoli
et al., 2020; Mathian et al., 2020; Million et al., 2020; Tang
et al., 2020; Yao et al., 2020). A post-exposure prophylaxis
randomised controlled trial of 821 participants failed to show any
benefit of hydroxychloroquine (n = 414) compared with placebo
(n = 407) (Boulware et al., 2020). At the time of writing, the
RECOVERY trial (Clinical Trial Identifier NCT04381936), which is
the largest randomised control trial so far conducted for the treat-
ment of COVID, has stopped recruiting to the hydroxychloroquine
arm (1,542 patients compared with 3,132 on standard care)
because of no beneficial effect in terms of either mortality or hos-
pital stay (Horby & Landray, 2020). There are still many other trials
ongoing testing the efficacy of hydroxychloroquine for either pro-
phylaxis or treatment.
Both chloroquine and hydroxychloroquine have been in clinical
use for many years for rheumatoid diseases, and thus, their safety
profile is well established. Dose-dependent retinal toxicity has long
been recognised as the major AE with long-term use of
chloroquine/hydroxychloroquine (Marmor et al., 2011). Besides retinal
toxicity, gastrointestinal, liver, and renal toxicity have also been
reported (Giner Galvan, Oltra, Rueda, Esteban, & Redon, 2007;
Michaelides, Stover, Francis, & Weleber, 2011; Mittal, Zhang, Feng, &
Werth, 2018). As both drugs are mainly metabolised in the liver and
excreted by renal clearance, their use in patients with liver or renal
impairment may worsen the function of these organs. For chloroquine
treatment, prescribing information recommends the full dose at all
degrees of renal impairment but suggests that monitoring of renal func-
tion may be useful (Sanofi-Aventis, 2017a). For hydroxychloroquine,
reductions in dosage are advised for patients with impaired renal func-
tion, as well as those taking concomitant medications with known risks
of kidney damage (Concordia Pharmaceuticals Inc., 2017).
A serious AE associated with chloroquine/hydroxychloroquine is
cardiotoxicity, which can take many forms including cardiomyopathy
in rare instances. Prolonged treatment or high dosage of
chloroquine/hydroxychloroquine has been shown to increase the risk
of QT interval prolongation, polymorphic ventricular tachycardia, and
sudden cardiac death (Chatre, Roubille, Vernhet, Jorgensen, &
Pers, 2018). A large epidemiological analysis in patients with rheuma-
toid arthritis has recently shown that 30-day cardiovascular mortality
was increased by more than twofold when hydroxychloroquine was
combined with azithromycin. The lethal ventricular arrhythmias are
primarily due to inhibition of a potassium channel (the inward rectifier
Kir2.1 channel) and may occur at low micromolar concentrations
(IC50 = 8.7 μM) (Rodriguez-Menchaca et al., 2008). While therapeutic
doses of chloroquine typically result in plasma concentrations of
2–5 μM, much higher concentrations in the heart are expected based
on a 400-fold increase observed in rat PK studies (McChesney,
Banks, & Fabian, 1967; Walker, Dawodu, Adeyokunnu, Salako, &
Alvan, 1983). Both drugs act on various potassium channels including
the inward rectifier currents (carried by Kir2.1 and Kir6.2 channels)
and rapid delayed rectifier currents (carried by Kv11.1/hERG
channels) (Ponce-Balbuena et al., 2012; Rodriguez-Menchaca
et al., 2008; Sánchez-Chapula, Navarro-Polanco, Culberson, Chen, &
Sanguinetti, 2002). The binding of chloroquine to the inward rectifier
Kir2.1 channel can be stabilised by negatively charged and aromatic
amino acids (Rodriguez-Menchaca et al., 2008). To a lesser extent,
chloroquine also blocks the rapid delayed rectifier current, IKr, possibly
through cation–π and π-stacking interactions withTyr652 and Phe656
in the S6 domain of hERG channels (Sánchez-Chapula et al., 2002).
The effect of inhibition of these potassium channels on the heart rate
appears to be complex. However, blocking the hERG channel has
proven to be the most common mechanisms by which drugs cause QT
interval prolongation (Traebert & Dumotier, 2005). The binding of
chloroquine/hydroxychloroquine to proteins is also stereoselective,
but whether one of the chloroquine/hydroxychloroquine enantiomers
has a stronger interaction with the Kir2.1 channel is not known. Cau-
tion is needed when hydroxychloroquine is used in combination with
other drugs (including azithromycin), which increase the QT interval
because of a pharmacodynamic synergistic interaction.
Given the co-morbidities in many patients with COVID-19, espe-
cially those with underlying cardiovascular disease, and the fact that
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COVID-19 itself is associated with cardiac manifestations, this may
increase the risk of cardiotoxicity associated with the use of
chloroquine/hydroxychloroquine. Indeed, excessive QTc prolongation
was observed in 36% of patients reported by Bessiere at al., and
greater QTc prolongation was also seen in patients taking the combi-
nation of hydroxychloroquine and azithromycin than those taking
hydroxychloroquine alone, highlighting the importance of pharmaco-
dynamic interactions (Bessiere et al., 2020; Mercuro et al., 2020). Fur-
thermore, a Phase IIb trial in Brazil showed that a higher dose of
chloroquine (600 mg twice daily) in patients hospitalised with COVID-
19 had a higher fatality rate (30%) compared with 15% in the lower
dose (450 mg twice daily) group (Borba et al., 2020). QTc interval pro-
longation >500 ms was observed in 19% of the high-dose group com-
pared with 11% of the low-dose group. The US prophylaxis
randomised control trial however did not show any increase in cardio-
vascular AEs (Boulware et al., 2020). We await the publication of the
RECOVERY trial to determine whether there was an excess of cardio-
vascular events. However, it is important to note that despite the size
of the RECOVERY trial (n = 1,542 patients), it may still be underpow-
ered to identify an excess number of cardiovascular events when
compared with standard of care.
3.3 | Remdesivir
Remdesivir is an investigational compound that was developed for
the treatment of Ebola (Mullard, 2018; Tchesnokov, Feng, Porter, &
Gotte, 2019). Remdesivir is a monophosphoramidate prodrug and acts
as a broad-spectrum antiviral that can be incorporated into viral RNA
(Agostini et al., 2018; Sheahan et al., 2020; Warren et al., 2016). Many
antivirals are proving to be ineffective against COVID-19 due to the
presence of a proofreading exoribonuclease (ExoN) specific to cor-
onaviruses, encoded in non-structural protein 14 (nsp14) (Agostini
et al., 2018). Remdesivir is able to evade this viral proofreading, all-
owing its incorporation into viral RNA and resulting in inhibition of
RNA-dependent RNA polymerases (RdRps), thereby preventing sub-
sequent viral replication (Warren et al., 2016). Furthermore, Arshad
et al. (2020) suggest that the maximum serum concentration (Cmax) of
remdesivir is sufficient to inhibit 90% of SARS-CoV-2 replication, a
parameter that is suspected to be of vital importance in the treatment
of COVID-19.
Remdesivir is administered intravenously, with single doses rang-
ing between 3 and 225 mg being well tolerated in Ebola patients
(n = 8) (ClinicalTrials.gov, 2019). Similar observations were made in
the blinded, placebo-controlled multiple-dose studies, during which
Ebola patients (n = 8) received an intravenous infusion of 150-mg
remdesivir daily for either 7 or 14 days, and only Grade 1 and
2 adverse reactions were reported (ClinicalTrials.gov, 2019). The pro-
posed dosing regimen for COVID-19 patients receiving remdesivir via
the UK Early Access to Medicines Scheme (EAMS) is similar to that
was evaluated for Ebola treatment: a loading dose of 200 mg on Day
1, followed by 100 mg daily for 5–10 days depending on symptom
severity (MHRA, 2020b). As such, it is likely that many of the AEs
observed in the Ebola study will translate to COVID-19 patients
treated with remdesivir.
Mild-to-moderate elevation of ALT and aspartate transaminase
(AST) were observed in several Ebola patients during the multiple-
dose study, reflecting observations made in human hepatocytes
in vitro (ClinicalTrials.gov, 2019; WHO, 2018). This is likely to be due
to the high cell permeability of hepatocytes, in combination with the
effective intracellular metabolism of remdesivir to its active form
within the liver (WHO, 2018). Emerging data have suggested that
SARS-CoV-2 may target ACE2 on hepatocytes leading to liver injury
as shown by a significant increase in ALT and bilirubin in severe cases
of COVID-19 (Guan et al., 2020). Therefore, it is likely that differenti-
ating between COVID-19-induced transaminase elevations and those
induced by remdesivir presents challenges (Bangash, Patel, &
Parekh, 2020; Zhang, Shi, & Wang, 2020). However, a recent study
found that only 4.1% of COVID-19 patients receiving remdesivir
treatment suffered serious (Grade 3 or 4) transaminase elevations,
with there being no significant difference between the remdesivir-
and placebo-treated groups (Beigel et al., 2020). These data imply that
remdesivir is relatively well tolerated in SARS-CoV-2-positive
patients. Regardless, as advised by the drug manufacturer, daily liver
function tests are essential in any patients receiving remdesivir, with
suggested discontinuation of the drug in patients whose ALT levels
reach ≥5 times the upper limit of normal (ULN) (Gilead, 2020). Adher-
ing to these guidelines is of particular importance in patients with pre-
existing liver disease or in those taking other medications that can also
induce transient ALT and AST elevation (WHO, 2018).
The reported differences between preclinical and clinical data
regarding the safety of remdesivir highlight the inadequacies of preclin-
ical models in some contexts. For example, with regard to COVID-19, a
concerning element of theoretical toxicity is that which affects the
respiratory system. A study using mousemodels of Middle East respira-
tory syndrome coronavirus (MERS-CoV) found that remdesivir
improved pulmonary pathology in infected mice and rhesus monkeys,
and no respiratory toxicity was observed (Gilead, 2020; Sheahan
et al., 2020). In contrast, a respiratory safety study in rats showed that
remdesivir had no effects on tidal volume or minute volume, but did
increase respiratory rate, which returned to baseline by 24 h post-dose
(WHO, 2018). Clearly, increased respiratory rate is a manifestation of
COVID-19, and there would be problems in assessing causality if
remdesivir was also likely to cause of respiratory problems in a clinical
setting. Fortunately, a recent double-blind, randomised, placebo-
controlled trial showed there to be no significant differences in adverse
respiratory events between the remdesivir-treated and control arms
(Beigel et al., 2020). In addition to this, preclinical safety studies per-
formed in rats and cynomolgus monkeys suggested that the kidney was
the target organ for remdesivir-induced toxicity (Gilead, 2020). This
was a significant concern before the initial COVID-19 clinical trials, as it
is known that SARS-CoV-2 can cause acute kidney failure in severe
cases (Ronco, Reis, & Husain-Syed, 2020). However, this has not been
reflected in COVID-19 clinical trials, where the presence of biomarkers
indicative of renal injury has not differed in patients treated with
remdesivir, compared with those on placebo (Beigel et al., 2020;
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Gilead, 2020). However, due to the inclusion of the solubility enhancer
sulfobutylether β-cyclodextrin sodium (SBECD) within remdesivir for-
mulations, remdesivir is contraindicated in patients with severe renal
impairment (eGFR < 30mlmin−1) (EuropeanMedicines Agency, 2020).
Finally, remdesivir is not exempt from DDIs. Co-administration of
remdesivir with several antibiotics including rifampicin is con-
traindicated, which could cause problems for any patients being
treated concomitantly for tuberculosis (Liverpool Drug Interaction
Group, 2020). This occurs because of enzyme induction that reduces
systemic exposure to remdesivir. A similar interaction has also been
seen with enzyme-inducing anticonvulsants, including carbamazepine,
phenytoin, and phenobarbital (Liverpool Drug Interaction
Group, 2020), where reduction in remdesivir exposure may lead to
inadequate treatment of COVID-19.
3.4 | Favipiravir
Favipiravir is another broad-spectrum antiviral prodrug that
undergoes intracellular phosphoribosylation to produce its active
form, favipiravir-ribofuranosyl-50-triphosphate (favipiravir-RTP)
(Furuta, Komeno, & Nakamura, 2017). It is thought that this antiviral
primarily acts by inducing lethal mutagenesis of RNA viruses, although
it also selectively and potently inhibits viral RdRp by acting as a pseu-
dopurine nucleotide (Dawes et al., 2018; Sangawa et al., 2013).
Favipiravir is currently licenced in Japan for the treatment of novel
and re-emerging influenza (Furuta et al., 2013; Furuta et al., 2002). Its
extensive spectrum of activity against various RNA virus polymerases
led to favipiravir being cited as a potentially “crucial pandemic tool,”
even before the outbreak of the novel coronavirus, COVID-19
(Adalja & Inglesby, 2019).
The PK of favipiravir was initially characterised in healthy Japa-
nese volunteers (Madelain et al., 2016). A Cmax of 51.5 μgml−1 was
found to occur 2 h post-administration, but plasma concentrations
decreased rapidly due to the relatively short half-life of favipiravir
(between 2 and 5.5 h) (Madelain et al., 2016). However, both Cmax and
half-life increase slightly after multiple doses, and it has been
suggested that favipiravir is capable of reaching a Cmax in humans suf-
ficient to inhibit 90% of SARS-CoV-2 replication, thus establishing it
as an important compound in the ongoing search for COVID-19 thera-
pies (Arshad et al., 2020).
Marked differences in Cmax have been observed between Japanese
and American patients with Cmax values in Japanese subjects being on
average 13.26 μgml−1 greater than those in American subjects
(Pharmaceuticals and Medical Devices Agency [PMDA], 2014). This
highlights the need for relevant COVID-19 clinical trials to include a
diverse range of subjects so that factors such as weight and ethnicity
can be considered to optimise dose. The bioavailability of favipiravir is
high at 97.6%, and only 54% of the drug is plasma protein bound,
suggesting that high tissue penetration would be likely (Madelain
et al., 2016; PMDA, 2014). in vivo work in mice showed that the half-
life of favipiravir in the lungs is double than that of favipiravir in plasma,
indicating slower elimination from the lungs (PMDA, 2014). This is
thought to be of high importance in COVID-19, where viral load is par-
ticularly high in the lungs. For influenza treatment in adults, 1,600-mg
favipiravir is given twice on Day 1 of treatment, followed by 600 mg
twice daily from Days 2 to 5 (PMDA, 2014). However, the dosing
period has been extended in ongoing COVID-19 clinical trials: up to
10 days in ChiCTR2000029996 and 14 days in ChiCTR2000029548
(Guan et al., 2020). It is therefore essential that all PK parameters are
monitored in these trials as differences, including increased Cmax and
decreased clearance, are expected during this prolonged dosing regi-
men that may affect safety.
Favipiravir has been linked to teratogenicity and embryotoxicity
and is therefore contraindicated in pregnancy (Furuta et al., 2013).
Overall, favipiravir is generally thought to have a good safety profile
(Asrani, Devarbhavi, Eaton, & Kamath, 2019; Liverpool Drug Interac-
tion Group, 2020; National Health Service [NHS], 2019). This is likely
to be due to the fact that unlike other antiviral drugs such as ribavirin,
favipiravir does not appear to disrupt nonviral RNA or DNA synthesis.
However, very little is known about the long-term safety of
favipiravir, as in previous clinical trials, patient follow-up has been as
little as 5 days (Pilkington, Pepperrell, & Hill, 2020). This is perhaps
less of a concern in COVID-19 as treatment is time limited.
Drug–drug interactions have been reported with favipiravir. For
example, coadministration with favipiravir can increase exposure to
paracetamol by around 15%, which may be a concern for patients
with pre-existing liver disease, as paracetamol is the leading cause of
acute drug-induced liver injury (DILI) in the United Kingdom and
United States (Asrani et al., 2019; Liverpool Drug Interaction
Group, 2020). Favipiravir can also increase patient exposure to many
contraceptives, including progesterone-only pills, combined pills, and
several contraceptive implants, which may cause discomfort, pro-
longed vaginal bleeding, and nausea (Liverpool Drug Interaction
Group, 2020; NHS, 2019). Whether the increased exposure to
oestrogens caused by concomitant treatment with favipiravir can
enhance the risk of thrombosis is not known but should be monitored,
given the overwhelming evidence that COVID-19 increases the risk of
blood clots (Atallah, Mallah, & AlMahmeed, 2020; Di Micco
et al., 2020; Spiezia et al., 2020). Interestingly, large clots are most
common in patients under the age of 50; almost 25% of women aged
between 15 and 49 in the United States currently use either oral or
long-acting contraceptives and thus represent a particular risk group
(Hurley, 2020; Centers for Disease Control and Prevention, 2019).
4 | MODULATION OF THE INFLAMMATORY
PHASE
SARS-CoV-2 virus is capable of eliciting an immune reaction in the
infected individual. Laboratory tests have shown that inflammatory
factors such as IL-6, IL-1, IL-10, and TNF-α are up-regulated during
infection and can instigate an inflammatory response in the lower air-
ways leading to lung injury in some instances (Conti et al., 2020; Guo
et al., 2020). Additionally, in patients with severe symptoms of
COVID-19, there may be activation of a cytokine storm, which can
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cause significant tissue damage (Mehta et al., 2020; Shi et al., 2020). A
smaller proportion of patients can progress to a hyperinflammatory
state, which in COVID-19 has been suggested to resemble secondary
haemophagocytic lymphohistiocytosis (sHLH), a rare syndrome
characterised by uncontrollable fever, cytopenia, raised ferritin levels,
and acute respiratory distress (Seguin, Galicier, Boutboul, Lemiale, &
Azoulay, 2016). IL and TNF-α levels show the greatest increase
in those who require admission to the intensive care unit
(ICU), suggesting that the cytokine storm is instrumental in severe
COVID-19 cases (Huang et al., 2020). Therefore, there has been a log-
ical progression towards the use of immunosuppressive agents as
potential therapies to alleviate inflammation and hyperinflammation
associated with COVID-19 (Mehta, McAuley, et al., 2020).
4.1 | Glucocorticoids
Dexamethasone is a glucocorticoid that can be administered both
orally and intravenously. It acts as a glucocorticoid receptor agonist
and is over 20 times more potent than endogenous cortisol, thus
resulting in dose-dependent suppression of pro-inflammatory genes
through a number of pathways in common with other steroids
(Papich, 2016; Whelan & Apfel, 2013; Yasir & Sonthalia, 2019). Low
doses of glucocorticoids have an anti-inflammatory effect, while
higher doses are immunosuppressive (Buttgereit et al., 2002). Dexa-
methasone can be used for inflammatory diseases such as rheumatoid
arthritis (Crohn's & Colitis Foundation, 2018; Freeman, 2008), but is
recommended for short-term treatment (spanning from 1 to 21 days)
because of the major adverse effects that can occur with long-term
treatment. One of the commonest uses of dexamethasone is for
reducing cerebral oedema.
As of July 8, 2020, dexamethasone was undergoing evaluation
in 17 clinical trials. On June 16, the results of the dexamethasone
arm of the RECOVERY trial were announced. The trial results, which
are available in preprint form, showed that 2,104 patients had
received either oral or intravenous low-dose (6 mg) dexamethasone
daily for 10 days (Horby et al., 2020). When compared with 4,321
control patients receiving usual care only, it was shown that dexa-
methasone reduced deaths by one third in SARS-CoV-2-positive
patients requiring ventilation and by one fifth in patients
receiving oxygen. No benefit was observed for patients with milder
COVID-19 symptoms who did not require respiratory support
(Horby et al., 2020).
Recent work has found that tissue inflammation and organ dys-
function seen in fatal cases of COVID-19 are not consistent with
SARS-CoV-2 distribution in tissues and cells (Dorward et al., 2020).
Tissue-specific tolerance to the virus may be therefore important and
suggests that fatalities arising from COVID-19 may be mainly due to
host-mediated immune response rather than pathogen-mediated end-
organ inflammation. This is consistent with the dexamethasone result
in the RECOVERY trial.
Dexamethasone has a bioavailability of 70–78% and is 77% pro-
tein bound in plasma (Spoorenberg et al., 2014). It is 6-hydroxylated
by hepatic CYP3A4 to 6α- and 6β-hydroxy dexamethasone and can
also be reversibly metabolised to 11-dehydroxymethasone and back
to dexamethasone by renal corticosteroid 11-β-dehydrogenase 1
(Diederich et al., 1998; Diederich, Hanke, Oelkers, & Bähr, 1997;
Tomlinson, Maggs, Park, & Back, 1997). Unlike many glucocorticoids
that are predominantly excreted in urine, only about 10% of
dexamethasone is excreted in urine (Dexcel Pharma Technologies Ltd,
2019).
Glucocorticoids are generally safe drugs when given at low doses
and for short periods of time (<3 weeks), with the risk of AEs increas-
ing with dose and therapy duration (Yasir & Sonthalia, 2019). Short-
term use of dexamethasone can result in increased appetite, mood
changes, and insomnia, but most of the adverse reactions are self-
limiting (NHS, 2020). Dexamethasone can lead to B- and T-cell deple-
tion and hence lymphopenia (Marinella, 2020), which interestingly is
also found in up to 80% of patients with COVID-19 (Liu, Blet,
Smyth, & Li, 2020). However, despite this, the RECOVERY trial was
able to show mortality benefit in the most severely affected COVID-
19 patients. A critical issue may be the dose that is administered—in
RECOVERY, 6 mgday−1 was administered over 10 days, which is a
relatively low dose.
A recent systematic review and meta-analysis of corticosteroid
treatment in patients with coronavirus infection suggested that corti-
costeroids were associated with higher rates of bacterial infections,
longer time spent in hospital, and higher rates of mortality (Yang, Liu,
et al., 2020). However, most of the studies analysed in this meta-
analysis were retrospective observational studies, generally of poor
quality and did not analyse the effects according to steroid dose.
Other studies that have used low-to-moderate-dose corticosteroids
as treatment for diseases such as viral and bacterial pneumonia reflect
the results of the RECOVERY trial, with low-dose corticosteroids
resulting in decreased mortality and morbidity in patients with severe
pneumonia (Li et al., 2017; Stern et al., 2017). In these studies, low-to-
moderate-dose corticosteroids (40- to 50-mg prednisolone, which
equates to 6- to 7.5-mg dexamethasone) were given to patients for
between 7 and 10 days (Stern et al., 2017) (National Institute for
Health and Care Excellence, 2020b). In keeping with the known
adverse effects of corticosteroids, the systematic review showed that
hyperglycaemia was significantly more frequent in the corticosteroid-
treated group (Stern et al., 2017).
Dexamethasone can be involved in both PK and pharmacody-
namic interactions. Combining it with other immunosuppressants may
increase the risk of serious infection (National Institute for Health and
Care Excellence, 2020c). Co-treatment with ibuprofen or other
NSAIDs increases the risk of gastrointestinal bleeding (National Insti-
tute for Health and Care Excellence, 2020c), whilst its gluconeogenic
effects can lead to hyperglycaemia, which in diabetic patients can lead
to increased insulin doses being required (Consilient Health
Ltd., 2020). Dexamethasone is a CYP3A4 inducer and may therefore
interact with remdesivir, a CYP3A4 substrate, potentially reducing its
plasma exposure. Although clinicians should be aware of this interac-
tion, the risk is small given that both drugs are indicated for 10 days
or less.
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4.2 | IL-6 receptor inhibitors
Both tocilizumab and sarilumab are humanised anti-IL-6 receptor
monoclonal antibodies used for the treatment of moderate to severe
rheumatoid arthritis, whereas siltuximab is a chimeric, human–mouse
anti-IL-6 receptor monoclonal antibody used for treatment of multi-
centric Castleman disease (MCD) (Deisseroth et al., 2015; National
Institute for Health and Care Excellence, 2020e). Due to their long
half-life, IL-6 inhibitors do not need to be taken daily; however, given
that they are currently indicated for chronic diseases, patients receive
IL-6 inhibitor treatments for life or until treatment failure (Janssen
Biotech Inc, 2019; Roche Pharma, 2013; Sanofi-Aventis, 2017b).
Clinical trials to assess the efficacy and safety of tocilizumab,
sarilumab, and siltuximab for the treatment of the inflammatory phase
of COVID-19 are ongoing. Whilst the exact dosing regimens vary
between trials, COVID-19 patients will be receiving a single or short-
course intravenous infusion or subcutaneous injection of the IL-6
inhibitor (Clinical Trial Identifiers NCT04317092, NCT04315298,
NCT04327388, NCT04330638, and NCT04322188).
Due to their similarity, it is not surprising that tocilizumab,
sarilumab, and siltuximab have comparable safety profiles. Thus far,
evidence from clinical trials in patients with rheumatoid arthritis and
MCD or post-marketing has revealed that IL-6 inhibitors are generally
well tolerated. Participants were enrolled on these trials for a mini-
mum of 6 months and in some cases up to 24 months. Individuals with
diabetes, a history of recurrent infection, age ≥65, and corticosteroid
use have been shown to be at an increased risk of developing a more
serious infection following IL-6 inhibitor use (Jones et al., 2010). While
adverse reactions were typically seen following chronic IL-6 inhibitor
treatment, the potential for COVID-19 patients to develop an adverse
drug reaction (ADR) following a single or small number of doses
should not be ignored.
The most common infections reported in patients receiving
anti-IL6 therapy include skin infections, respiratory infections, uri-
nary tract infections, and, in some cases, opportunistic infections
ranging from tuberculosis to herpes (Emery et al., 2008; Emery
et al., 2019; Fleischmann et al., 2017; Fleischmann et al., 2013;
Genovese et al., 2015; Genovese et al., 2008; Genovese
et al., 2019; Hoshi et al., 2012; Huizinga et al., 2014; Janssen Bio-
tech Inc, 2019; Jones et al., 2010; Kameda et al., 2020; McCarty &
Robinson, 2018; Pawar et al., 2019; Smolen et al., 2008; Tanaka
et al., 2019; Weinblatt et al., 2013). Neutropenia has also been
reported with all three drugs when tested for their intended thera-
peutic use, and in some trials, this led to patient discontinuation
(Emery et al., 2008; Fleischmann et al., 2017; Fleischmann
et al., 2013; Genovese et al., 2015; Genovese et al., 2008; Huizinga
et al., 2014; Janssen Biotech Inc, 2019; Jones et al., 2010; Smolen
et al., 2008). Absolute neutrophil count (ANC) must be monitored
every 4–8 weeks, and in those who develop an ANC < 0.5 × 109 L-
1, treatment must be discontinued (National Institute for Health and
Care Excellence, 2020d; Roche Pharma, 2013; Sanofi-Aventis,
2017b). Gastrointestinal manifestations (upper abdominal pain,
mouth ulceration, and nausea) have also been reported with IL-6
inhibitors. A systematic review and meta-analysis of 35 COVID-19
studies found that 15% of patients experienced gastrointestinal dis-
turbance manifested as vomiting, diarrhoea, and loss of appetite.
This has been postulated to be due to the expression of ACE2 on
gastrointestinal epithelial cells (Mao et al., 2020; Qi, Qian, Zhang, &
Zhang, 2020). Therefore, differentiating between COVID-19-induced
gastrointestinal disorders and those evoked by IL-6 therapy may
present a challenge in terms of causality and the need to modify or
stop therapy. Increases in lipid profiles (total cholesterol, LDL, HDL,
and triglycerides) have also been reported in patients receiving IL-6
inhibitors as either monotherapy or combination therapy (Emery
et al., 2008; Fleischmann et al., 2013; Genovese et al., 2015; Geno-
vese et al., 2008; Genovese et al., 2019; Huizinga et al., 2014;
Janssen Biotech Inc, 2019; Jones et al., 2010; Kameda et al., 2020;
Smolen et al., 2008; Tanaka et al., 2019). However, the incidence of
major cardiovascular events was infrequent, and lipid elevation
resolved with statin therapy (Genovese et al., 2015; Genovese
et al., 2019).
Tocilizumab is associated with an increased risk of hepatotoxicity,
usually manifested as an asymptomatic rise in ALT (Anger et al., 2017;
Drepper, Rubbia-Brandt, & Spahr, 2013; Fleischmann et al., 2013;
Jones et al., 2010; Mahamid, Mader, & Safadi, 2011; Maini
et al., 2006; Nishimoto et al., 2009; Pawar et al., 2019; Smolen
et al., 2008). Liver injury has also been reported with a liver biopsy
from a female patient who had taken tocilizumab for a month reveal-
ing focal necrosis of hepatocytes with steatosis and early fibrosis
(Mahamid et al., 2011). COVID-19 also has effects on the liver, and
again, causality assessment may be difficult (Guan et al., 2020). The
prescribing instructions for tocilizumab and sarilumab indicate that
liver function tests are required every 4–8 weeks following treatment
commencement and then every 3 months thereafter (Roche
Pharma, 2013; Sanofi-Aventis, 2017b). If liver enzymes are 1–3×
ULN, the dose of tocilizumab and sarilumab can be reduced until ALT
or AST have normalised and then treatment resumed at the therapeu-
tic dose. Where laboratory findings are >3–5× ULN, treatment with
IL-6 inhibitors must be paused and then recommendations for 1–3×
ULN followed. If elevations persist or are >5× ULN, tocilizumab and
sarilumab treatment must be discontinued immediately (Roche
Pharma, 2013; Sanofi-Aventis, 2017b). Although sarilumab and
siltuximab are associated with abnormalities in liver function tests,
they are typically short lived and asymptomatic (LiverTox, 2016,
2017b). Pre-existing liver disease can worsen symptoms of DILI and in
some cases increase susceptibility (David & Hamilton, 2010).
Tocilizumab, sarilumab, and siltuximab are expected to undergo
metabolism via catabolic pathways and not CYP450 processes
(McCarty & Robinson, 2018). Therefore, due to the lack of hepatic
metabolism, it is assumed that the PK of the IL-6 inhibitors will not be
altered in patients with pre-existing liver disease (Abou-Auda &
Sakr, 2010). However, tocilizumab, sarilumab, and siltuximab have
been shown to restore and improve CYP levels (Janssen Biotech
Inc, 2019; Roche Pharma, 2013; Sanofi-Aventis, 2017b). This is of par-
ticular importance as CYP levels may remain elevated following treat-
ment discontinuation due to the long half-life of the compounds.
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Therefore, this may be a consideration for further evaluation for any
dosing adjustment requirements if patients are taking medications
that are metabolised by CYP enzymes.
4.3 | IL-1 receptor inhibitors
Anakinra is a 17-kD, recombinant human IL-1 receptor antagonist
that blocks the activity of pro-inflammatory cytokines IL-1α and
IL-1β (Cawthorne et al., 2011; Dinarello, Simon, & van der
Meer, 2012). Anakinra is primarily used in combination with
methotrexate for reducing the symptoms and slowing the progres-
sion of joint damage in rheumatoid arthritis (National Institute for
Health and Care Excellence, 2020a). It is also used for rare inflam-
matory conditions such as cryopyrin-associated periodic syndromes
and Still's disease (National Institute for Health and Care
Excellence, 2020a). It is administered via subcutaneous injection
and is supplied as a single-use, pre-filled syringe containing
100 mg in 0.67 ml (Swedish Orphan Biovitrum Ltd, 2007). Rheu-
matoid arthritis patients and those with Still's disease and a body
weight >50 kg must be given 100-mg anakinra, whereas patients
with Still's disease with a body weight <50 kg should have weight-
based dosing starting at 1–2 mgkg−1 (Swedish Orphan Biovitrum
Ltd, 2007). The recommended starting dose for patients with
cryopyrin-associated periodic syndromes is 1–2 mgkg−1. If
tolerated, the dose can be increased from 3–4 mgkg−1 to a maxi-
mum of 8 mgkg−1 (Swedish Orphan Biovitrum Ltd, 2007). Anakinra
has a short terminal half-life of approximately 4–6 h and so must
be administered daily, preferably at the same time each day
(Amgen Inc., 2001). Anakinra is currently not licenced for intrave-
nous administration or treatment of sHLH, but its use is endorsed
by clinicians, where intravenous infusion, as opposed to subcutane-
ous injection, can achieve quicker and greater maximal plasma
concentrations (Carter, Tattersall, & Ramanan, 2018; La Rosée
et al., 2019; Mehta, Cron, Hartwell, Manson, & Tattersall, 2020).
Thus far, 21 clinical trials have been registered to assess the use
of anakinra in patients with severe COVID-19. Additionally, two
recent studies have reported positive outcomes with anakinra in
COVID-19-induced acute respiratory distress syndrome (Cavalli
et al., 2020; ClinicalTrials.gov, 2020c; Huet et al., 2020). Participants
were dosed 100 mg twice daily subcutaneously for 72 h followed by
100 mg daily for 7 days in addition to standard of care (Huet
et al., 2020). This retrospective study found that anakinra reduced
rates of mortality and the need for mechanical ventilation in ICU
patients (Huet et al., 2020). Anakinra was administered either subcu-
taneously or intravenously in the COVID-19 Biobank Study (Huet
et al., 2020). Participants received subcutaneous injections at a dose
of 100 mg twice daily or via slow intravenous infusion at
10 mgkg−1day−1 until there was a 75% reduction in serum C-reactive
protein levels and sustained respiratory improvements (Cavalli
et al., 2020). Alhtough no safety concerns emerged with anakinra
administered subcutaneously, it was discontinued due to a lack of clin-
ical improvement and limited reduction in C-reactive protein (Cavalli
et al., 2020). By contrast, intravenous anakinra was well tolerated and
improved clinical outcomes. Notably, 72% of patients had improved
respiratory function in comparison with 50% within the standard
treatment group (Cavalli et al., 2020). In both studies, cases of
ALT ≥ 3× ULN were observed in both the anakinra and the standard
treatment arms. Four cases of bacteraemia following intravenous
anakinra were reported in the COVID-19 Biobank Study, but there
were no cases of bacterial infection in the Ana-COVID Study (Cavalli
et al., 2020; Huet et al., 2020). While both studies are encouraging,
they should be considered proof-of-concept trials, and larger
randomised trials are still needed (Cavalli et al., 2020; Huet
et al., 2020).
Subcutaneous administration of anakinra is associated with injec-
tion site reactions (Kaiser et al., 2012). In a review of five rheumatoid
arthritis clinical trials, 71% of participants receiving anakinra therapy
reported injection site reactions in comparison with 28% of partici-
pants on placebo (Mertens & Singh, 2009). Injection site reactions can
range from immediate to delayed. In immediate cases, the reaction
manifests as a burning sensation whereas delayed reactions present
as a rash, pruritus, or swelling (Kaiser et al., 2012). Anakinra has also
been reported to lead to infection, neutropenia, thrombocytopenia,
headache, and blood cholesterol increase when administered subcuta-
neously (Swedish Orphan Biovitrum Ltd, 2007).
Injection site reactions that arise immediately can be eased by
placing an ice pack on the injection site before and after anakinra
administration, and delayed reactions can be treated with topical cor-
ticosteroids or antihistamines (Kaiser et al., 2012). Increases in serious
infection rate are common following anakinra use and frequently
include upper respiratory infections, sinusitis, urinary tract infection,
and bronchitis (Bresnihan et al., 1998; Cohen et al., 2002;
Fleischmann et al., 2003). Whilst rare, cases of opportunistic infection
have been reported in anakinra monotherapy or in those receiving
anakinra in combination with immunosuppressive agents (Salvana &
Salata, 2009; Swedish Orphan Biovitrum Ltd, 2007). Neutrophil
counts must be monitored during the first 6 months of anakinra treat-
ment and quarterly henceforth (Swedish Orphan Biovitrum
Ltd, 2007). In patients where the ANC is <1.5 × 109 cells L-1, treat-
ment must be discontinued immediately (Swedish Orphan Biovitrum
Ltd, 2007). The higher doses being used in COVID-19 trials and the
potential for a greater Cmax due to intravenous administration poten-
tially raise additional safety concerns. However, earlier detection of
AEs should be possible since the duration of treatment will be shorter
than that used in rheumatoid arthritis, coupled with the fact that
patients will already be hospitalised.
Anakinra is catabolised and eliminated via glomerular filtration
(Swedish Orphan Biovitrum Ltd, 2007; Yang, Baughman, &
Sullivan, 2003). Caution should be exercised, and dose adjustments
may be required in moderate to severe renal impairment (Swedish
Orphan Biovitrum Ltd, 2007; Yang et al., 2003). During general infec-
tions and inflammatory diseases, CYP enzymes are primarily down-
regulated (Mallick, Taneja, Moorthy, & Ghose, 2017). Similar to IL-6
inhibitors, it may be possible that anakinra treatment restores CYP
levels in infected patients (Swedish Orphan Biovitrum Ltd, 2007).
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Therefore, caution should be exerted in COVID-19 patients receiving
concomitant medications with a drug having a narrow therapeutic
window. Mild interactions can occur between anakinra and warfarin,
clopidogrel, clozapine, and phenytoin (Liverpool Drug Interaction
Group, 2020).
4.4 | JAK inhibitors
Baricitinib is an orally administered, disease-modifying, anti-rheumatic
drug (DMARD), traditionally used in the treatment of moderate to
severe active rheumatoid arthritis (Al-Salama & Scott, 2018). By acting
as an ATP-competitive kinase inhibitor, baricitinib can selectively and
potently inhibit JAK1 and JAK2 in a reversible manner. JAKs are
essential in the transduction of intracellular signals for various cyto-
kines involved in the inflammatory and immune responses, and so by
inhibiting these kinases, baricitinib is able to relieve symptoms of
rheumatoid arthritis for many patients (Fridman et al., 2010).
As described previously, a common characteristic of COVID-19,
much like another betacoronavirus disease SARS, is a profuse inflam-
matory response (Huang et al., 2020; Stebbing et al., 2020). Increased
levels of pro-inflammatory cytokines, such as IFN-γ and IL-1β, have
been observed in confirmed COVID-19 cases (Huang et al., 2020;
Mehta, McAuley, et al., 2020; Russell et al., 2020). Furthermore, the
levels of some specific cytokines appear to be related to disease
severity; patients requiring admission to intensive care units show
increased levels of TNF-α and the chemokine CCL2. The rationale
behind repurposing baricitinib as a treatment for COVID-19 is centred
on this potential for severely ill patients to present with a cytokine
storm (Mehta, McAuley, et al., 2020; Russell et al., 2020). By dampen-
ing the inflammatory response, it is postulated that baricitinib will be
able to relieve COVID-19 symptoms. Data modelled using artificial
intelligence techniques suggest that baricitinib may work by inhibiting
virus entry into cells via an endocytic regulator known to be involved
in coronavirus internalisation, the AP2-associated protein kinase
1 (AAK1) (Burkard et al., 2014; Richardson et al., 2020). Baricitinib, as
well as being capable of JAK1 and JAK2 inhibition, is a high-affinity
inhibitor of AAK1 (Richardson et al., 2020).
Patients tend to tolerate baricitinib well, and it has a relatively
good safety profile (Keystone et al., 2015). However, as with
tocilizumab and sarilumab treatment, a very common (≥1/10) AE
observed in patients taking baricitinib, but not in the placebo arm, is
upper respiratory tract infection, which may be related to its ability to
suppress the immune system (Eli Lilly, 2017). Patients taking bari-
citinib have the potential to develop respiratory tract infections, which
may make it difficult to distinguish whether any deterioration is due
to COVID-19 or a secondary infection. Other opportunistic infections
including herpes zoster and urinary tract infections were also more
common in the treated arm compared with placebo, and dose reduc-
tion is recommended for patients with a history of chronic infections
(Eli Lilly, 2017; Smolen et al., 2018). Secondary infections are not
uncommon in severe COVID-19 patients, and so the use of a drug
that may make patients increasingly prone to infections will depend
on the harm–benefit ratio for severe cases of COVID-19
(WHO, 2020a).
Baricitinib is currently still being trialled in patients with COVID-
19 with a therapeutic dose of 2–4 mg once daily, which is the same as
the recommended dosage for the treatment of rheumatoid arthritis
(Cantini et al., 2020; Richardson et al., 2020). There have been a small
number of reports from patients taking this recommended dosage for
the treatment of rheumatoid arthritis presenting with deep vein
thrombosis (DVT), which was severe in some of these cases (Taylor
et al., 2019). This is a cause for concern as there are increasing reports
of COVID-19 patients, especially those who are critically ill and in the
ICU, with thrombotic complications including pulmonary embolism
and other venous and arterial thrombotic events (Klok et al., 2020;
Middeldorp et al., 2020). As baricitinib has been reported to cause
DVT, there is the potential for disease–drug interactions with COVID-
19 patients taking baricitinib potentially more likely to develop throm-
botic complications. In order to mitigate this risk, alternative JAK
inhibitors, which have a lower risk of thrombotic events, such as
ruxolitinib, may be considered in the context of COVID-19 (Alvarez-
Larran et al., 2018). However, unlike baricitinib, ruxolitinib is primarily
metabolised by CYP3A4 (Yang & Keating, 2012). This means that pre-
scribing ruxolitinib instead of baricitinib may increase the risk of
CYP3A4-related DDIs (Ogu & Maxa, 2000). Baricitinib is not predicted
to be involved in any problematic DDIs. Co-administration with both
CYP3A inhibitors (fluconazole) and inducers (rifampicin) failed to
result in any clinically relevant changes to baricitinib exposure (Eli
Lilly, 2017).
Emerging reports have revealed that patients with COVID-19
experience renal impairment, which could be attributed to ACE2
expression on kidney endothelial cells (Varga et al., 2020). Baricitinib
should not be given to patients with renal impairment as the majority
of the drug is cleared through the kidneys, and monitoring of renal
function will be important to prevent AEs related to overexposure to
baricitinib in those with deteriorating renal function (Eli Lilly, 2017).
5 | STIMULATION OF THE BODY'S
ANTIVIRAL RESPONSE
5.1 | IFN-β
Type 1 IFNs are a group of cytokines produced during viral infection.
Notably, IFN-β-1a has a leading role in activating genes involved in
immunomodulation, suppressing the inflammatory response and ant-
iviral effects (Sallard, Lescure, Yazdanpanah, Mentre, & Peiffer-
Smadja, 2020). While a variety of type 1 IFNs exist, in vitro evidence
has shown that IFN-β-1a and IFN-β-1b are the most potent in the
inhibition of SARS-CoV and MERS-CoV (Chan et al., 2013; Hensley
et al., 2004). Within the lungs, IFN-β-1 has been shown to up-regulate
levels of the enzyme CD73, an ecto-5'-nucleotidase, which inhibits
vascular leakage, increases the secretion of anti-inflammatory adeno-
sine, and preserves pulmonary endothelial barrier function (Kiss
et al., 2007; Sallard et al., 2020). However, in vivo research has
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revealed that timing of administration of IFN-β-1 is crucial for positive
effects. When administered shortly after MERS-CoV infection, IFN-
β-1 protected mice from lethal infection, whereas delayed administra-
tion failed to effectively inhibit viral replication or pro-inflammatory
cytokines, leading to fatal pneumonia (Channappanavar et al., 2019).
Interestingly, in vitro evidence has revealed that SARS-CoV-2 is more
sensitive to IFN-β-1 treatment than MERS-CoV and SARS-CoV and
thus supports the tenet that treatment with IFN-β-1 may be beneficial
for COVID-19 patients (Lokugamage, Schindewolf, &
Menachery, 2020; Sheahan et al., 2020; Thiel & Weber, 2008). It is
assumed that treatment of COVID-19 patients with IFN-β-1 will
strengthen the host immune response and prevent the worsening of
severe respiratory tract manifestations.
IFN-β-1 therapy has been used for the long-term management of
multiple sclerosis (MS) and has been associated with a number of AEs.
When administered subcutaneously in MS patients, the most common
AEs were flu-like symptoms, injection site reactions, worsening of MS
symptoms, menstrual disorders, mood alterations, and laboratory
abnormalities (Walther & Hohlfeld, 1999). The most common labora-
tory abnormalities were neutropenia, leukopenia, lymphopenia, and
raised aminotransferases (Walther & Hohlfeld, 1999). A genome-wide
association study of patients with IFN-β induced liver injury showed
that rs2205986, which has been linked to differential expression of
IFN regulatory factor (IRF)-6, is a predisposing factor (Kowalec
et al., 2018). This may be related to the fact that IRF6 leads to apopto-
sis in the presence of IFN-β. Depression is a common AE reported in
patients receiving subcutaneous IFN-β-1 therapy, and thus, caution is
needed when administering to those with a previous or current his-
tory of depressive disorder (Biogen, 2007). Whilst rare, careful moni-
toring of clinical manifestations such as new onset hypertension,
thrombocytopenia, impaired renal function, and fever is required in
order to identify cases of thrombotic microangiopathy (TMA)
(Biogen, 2007). TMA is rare and has been reported at different time
points of IFN-β-1 therapy (Biogen, 2007; Nishio et al., 2016; Yam,
Fok, McLean, Butler, & Kempster, 2018). Laboratory findings of a
decreased platelet count, increased serum LDH, and red blood cell
fragmentation are suggestive of TMA (Biogen, 2007). If diagnosed,
patients must discontinue IFN-β-1 therapy and will require plasma
exchange (Biogen, 2007).
SNG001 is an inhaled form of IFN-β-1a produced by Synairgen.
The company has tested the efficacy and safety of the drug for the
prevention and treatment of symptoms associated with respiratory
viral infection in asthma and chronic obstructive pulmonary disease
(COPD) (Synairgen plc, 2018). A randomised, placebo-controlled,
Phase 2 trial is currently ongoing to assess the safety and efficacy of
inhaled SNG001 for the treatment of patients with COVID-19
(NCT04385095). Data from the asthma trials have revealed that when
administered via inhalation, high levels of IFN-β-1a are achieved
within the lungs with lower levels within the circulation leading to
improvements in lung function, antiviral responses, and better asthma
control (Djukanovic et al., 2014). Inhaled SNG001 seems to have a
good safety profile; five patients within the SNG001 arm reported
cardiac palpitations, whereas no cases were reported in the placebo
arm, but symptoms were mild and not considered clinically significant
(Djukanovic et al., 2014).
A clinical trial has been undertaken in hospitalised COVID-19
patients where the triple combination of IFN-β, lopinavir–ritonavir,
and ribavirin was compared with lopinavir–ritonavir and ribavirin
(Hung et al., 2020; Shalhoub, 2020). Patients in the triple combination
therapy arm achieved negative COVID-19 tests results faster than
those in the control arm, with improved patient symptoms, decreased
viral shedding, and decreased overall length of stay in the hospital
compared with those in the control group (Hung et al., 2020). AEs
reported in both groups included nausea and diarrhoea. However, due
to polypharmacy in this trial, it was difficult to determine the effect of
IFN-β on SARS-CoV-2 alone.
IFN-β has reported DDIs with other COVID-19 therapies includ-
ing chloroquine and hydroxychloroquine and with anakinra, sarilumab,
and tocilizumab (Liverpool Drug Interaction Group, 2020). DDIs have
also been reported with metamizole (analgesic), linezolid
(antibacterial), clozapine (antipsychotic), zidovudine (HIV antiretroviral
therapy), and some immunosuppressants (adalimumab, azathioprine,
and pirfenidone) (Liverpool Drug Interaction Group, 2020).
6 | FUTURE OUTLOOK
Reviewing the safety of potential COVID-19 treatments (Table 1) is
complex due to the fast-moving pace of research in this field. For
example, chloroquine and hydroxychloroquine with or without an
accompanying macrolide antibiotic have consistently been at the fore-
front of COVID-19 research efforts since the outbreak began. How-
ever, the astonishing developments over a week or so have led to
retraction of a highly publicised paper, and results from a post-
exposure prophylaxis trial and a treatment trial (RECOVERY), both of
which have shown no beneficial effect of hydroxychloroquine
(Boulware et al., 2020; Horby & Landray, 2020; Mehra, Ruschitzka, &
Patel, 2020). This highlights that the rapid rate of discoveries sur-
rounding COVID-19 therapies generates the need to update this per-
spective frequently, in order to ensure that the safety of any newly
repositioned therapies, novel developmental compounds or new ther-
apeutic combinations are investigated. For example, the potential use
of heparin in novel forms, including nebulised therapy (Clinical Trial
Identifier NCT04397510), as an antiviral agent is currently the subject
of several investigational trials. In addition, the potential utility of
nitazoxanide is currently the subject of several clinical trials
(ClinicalTrials.gov, 2020a; Pepperrell, Pilkington, Owen, Wang, &
Hill, 2020; Rajoli et al., 2020).
It is clearly essential that the harm–benefit ratio of any
pharmacogical agent being considered for use in the treatment of
COVID-19 is thoroughly considered. This ratio changes dependent
upon the disease stage and is correlated to potential mortality. For
example, a higher risk may be acceptable for patients in the later
stage of severe disease but not acceptable when the same thera-
peutic agent is administered in mild disease. This difference in
harm–benefit analysis becomes even more striking when
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considering the use of such agents to prevent infection. As is the
case for many highly contagious viruses, prevention by prophylaxis
would be incredibly valuable. Some of the agents described in this
review, including chloroquine and ritonavir, have been suggested
as potential prophylactic agents, but to date, data on efficacy have
been disappointing (Rathi, Ish, Kalantri, & Kalantri, 2020; Spinelli,
Ceccarelli, Di Franco, & Conti, 2020). Clearly, treatment duration
for prophylaxis is expected to be longer than for treatment of
COVID-19, and this may further alter the harm–benefit ratio,
reinforcing the need for safety considerations at the outset of any
clinical trials.
Similarly, the evaluation of therapy risk also applies to long-term
recovery. As the current pandemic progresses, it is becoming appar-
ent that being discharged from hospital does not necessarily mean
that patients are free from COVID-19 symptoms. Large numbers of
patients who have survived severe SARS-CoV-2 infection may have
incurred long-term health problems, including some permanent loss
of lung and kidney function (Foundation, 2020; Su et al., 2020;
Summers, 2020). Consequently, it is probable that long-term thera-
pies will be required for many patients to maintain or, ideally, restore
normal physiological organ function. It is vital that therapies that will
be used to treat patients during their long-term recovery are also
undergoing evaluation for their safety, particularly as many of these
agents may need to be administered over much longer periods of time
than initial COVID-19 treatments.
The identification and characterisation of biomarkers of disease
and safety will be invaluable in the further development and deploy-
ment of therapies for COVID-19. Disease biomarkers, for example, of
lung injury or the hyperinflammatory response, may allow the stratifi-
cation of therapy in order to select the agent best suited to the stage
of disease. Moreover, biomarkers should be considered to monitor
patient safety in cases of known AEs. For example, the manufacturer's
guidelines for remdesivir recommend daily liver function tests due to
the risk of transaminase elevations (Gilead, 2020). These tests are
essential, particularly with regard to COVID-19 where increased ALT
levels are reported to be common amongst hospitalised patients
(Bangash et al., 2020; Zhang et al., 2009). Looking to the future,
improvements in the specificity, predictivity, and reliability of drug-
induced organ damage, through academic–industry partnerships such
as the Biomarker Qualification Program in the Critical Path Institute
in the United States and the European Innovative Medicines Initiative
consortiumTransBioline, will help improve clinical assessment of drug
safety issues in COVID-19.
Continued enhancements in the speed, predictivity, and human
translation of safety assessment for toxicity of antiviral compounds is
clearly warranted, and this may include animal models of SARS-CoV-2
as well as in vitro models, in order to assess efficacy alongside safety.
Such a full understanding for individual therapies will indicate the
combinations that can have the potential to provide the best synergy
for benefit, while forewarning of the potential for increased risk/harm
through PK or toxicodynamic interaction.
Although outside the scope of this review, a vaccine for COVID-
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population. As of July 8, 2020, according to WHO, there are 21 vac-
cines in clinical trial stages and 139 in preclinical stages of evaluation
(WHO, 2020b). Currently, potential vaccines are only just beginning to
be tested for efficacy in humans in early phase studies, and therefore,
safety data will begin to emerge as larger numbers of individuals are
treated with the vaccine. Safety data regarding preliminary vaccina-
tions against SARS and MERS are limited, but the available informa-
tion may be useful during the development of COVID-19 vaccines,
due to the similarities between the coronavirus strains (Padron-
Regalado, 2020). One safety concern relevant to coronaviruses is the
potential for the induction of antibody-dependent enhancement
(ADE), a phenomenon that was observed in cats vaccinated against
feline infectious peritonitis coronavirus and has also been seen in
patients vaccinated against Zika virus and dengue virus (Khandia
et al., 2018; Padron-Regalado, 2020; Vennema et al., 1990). ADE can
occur when non-neutralising antibodies bind to virus particles and
increase their uptake into host cells, instead of rendering them non-
infectious (Padron-Regalado, 2020; Tirado & Yoon, 2003). This caused
concern in initial SARS vaccine development, but can reportedly be
avoided by using truncated versions of the viral S glycoproteins
(He et al., 2004). Acknowledging safety concerns such as this, as well
as the ways they can be attenuated, may be paramount in the timely
development of a vaccine against COVID-19.
In conclusion, although expanding extremely rapidly, the field of
therapies to treat COVID-19 remains in its infancy. Safety will con-
tinue to play a major role in therapeutic success, as apparent with
recent reports of increased cardiac toxicity associated with the use of
chloroquine/hydroxychloroquine in the treatment of COVID-19,
despite its long history of use as an antimalarial. Above all, this per-
spective has exemplified the need to view safety concerns in the
context of the individual and specific phase of disease in order to for-
mulate a comprehensive harm–benefit balance. Importantly, an
awareness of potential safety concerns will support the development
of the next stage of therapy targeting prophylaxis and recovery
post-COVID infection. It is imperative that safety scientists rise to the
challenge of COVID-19 by utilising their expertise in mechanistic
understanding, biomarker development, and toxicokinetic modelling in
order to support the development of COVID-19 therapies that can be
used effectively and safely.
NOMENCLATURE OF TARGETS AND LIGANDS
Key protein targets and ligands in this article are hyperlinked to
corresponding entries in the IUPHAR/BPS Guide to PHARMACOL-
OGY (http://www.guidetopharmacology.org) and are permanently
archived in the Concise Guide to PHARMACOLOGY 2019/20
(Alexander, Christopoulos, et al., 2019; Alexander, Cidlowski,
et al., 2019; Alexander, Fabbro, et al., 2019a, b; Alexander, Kelly,
et al., 2019; Alexander, Mathie, et al., 2019).
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